{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T09:18:10Z","timestamp":1788081490655,"version":"build-2784847793"},"reference-count":84,"publisher":"Portland Press Ltd.","issue":"05","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,29]]},"abstract":"<jats:p>Acute leukemias are hematological malignancies characterized by the uncontrolled proliferation of immature bone marrow cells, disrupting normal hematopoiesis. These diseases, classified into acute lymphoblastic leukemia and acute myeloid leukemia (AML), often result from acquired genetic alterations that drive deregulated cell growth and inhibit differentiation. The cytoskeleton has emerged as a promising therapeutic target due to its pivotal role in cellular processes such as adhesion, motility, and division. Among its components, stathmin 1 (STMN1) and ezrin (EZR) stand out for their significant involvement in the pathogenesis and progression of acute leukemias. STMN1, a regulator of microtubule dynamics, is associated with chromosomal instability and leukemic cell proliferation, and is frequently overexpressed in these malignancies. Anti-microtubule agents, such as paclitaxel, eribulin, and cyclopenta[b]indole derivatives have demonstrated the ability to inhibit STMN1 by inducing its phosphorylation at regulatory sites, thereby impairing cell viability and promoting apoptosis. EZR, a membrane-actin linker protein, plays a critical role in cell signaling and tumor survival. Its overexpression has been correlated with poor prognosis in AML. Pharmacological inhibitors like NSC305787 have shown efficacy in reducing cell viability, modulating key pathways such as PI3K (phosphatidylinositol-3-kinase)\/AKT (AKT serine-threonine protein)\/mTOR (mammalian target of rapamycin), and enhancing the activity of standard chemotherapeutics, thereby supporting their potential use in combination therapies. This review aims to explore the roles of STMN1 and EZR in the pathogenesis of acute leukemias, assessing their potential as therapeutic targets. The goal is to synthesize recent evidence to guide the development of more effective inhibitors, focusing on overcoming therapeutic resistance and tailoring treatments to individual profiles.<\/jats:p>","DOI":"10.1042\/bst20253017","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T16:30:18Z","timestamp":1758558618000},"page":"1249-1258","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New molecular targets in acute leukemias: cytoskeletal regulatory proteins"],"prefix":"10.1042","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2937-8109","authenticated-orcid":false,"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"first","affiliation":[{"name":"1Department of Pharmacology, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-3315","authenticated-orcid":false,"given":"Hugo Passos","family":"Vicari","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2569-5959","authenticated-orcid":false,"given":"Jean Carlos","family":"Lipreri da Silva","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5498-7539","authenticated-orcid":false,"given":"Keli","family":"Lima","sequence":"additional","affiliation":[{"name":"2Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"3Cancer Institute of the State of S\u00e3o Paulo, Faculdade de Medicina, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"2025103105511226100_BST-2025-3017C1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092256","article-title":"Etiology of acute leukemia: a review","volume":"13","author":"Tebbi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025103105511226100_BST-2025-3017C2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1159\/000362793","article-title":"Genomic characterization of acute leukemias","volume":"23","author":"Chiaretti","year":"2014","journal-title":"Med. Princ. Pract."},{"key":"2025103105511226100_BST-2025-3017C3","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"2025103105511226100_BST-2025-3017C4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2025103105511226100_BST-2025-3017C5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11899-019-00535-7","article-title":"Acute myeloid leukemia: from mutation profiling to treatment decisions","volume":"14","author":"DiNardo","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2025103105511226100_BST-2025-3017C6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-020-01944-5","article-title":"A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia","volume":"98","author":"Kirtonia","year":"2020","journal-title":"J. Mol. Med."},{"key":"2025103105511226100_BST-2025-3017C7","doi-asserted-by":"crossref","first-page":"150950","DOI":"10.1016\/j.soncn.2019.150950","article-title":"Acute leukemia: diagnosis and treatment","volume":"35","author":"Blackburn","year":"2019","journal-title":"Semin. Oncol. Nurs"},{"key":"2025103105511226100_BST-2025-3017C8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ajh.21801","article-title":"Acute leukemia presenting with extramedullary diseases and completely normal hemogram: an extremely unusual manifestation unique to pre-B ALL","volume":"85","author":"Chen","year":"2010","journal-title":"Am. J. Hematol."},{"key":"2025103105511226100_BST-2025-3017C9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.blre.2017.01.003","article-title":"Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia","volume":"31","author":"Percival","year":"2017","journal-title":"Blood Rev"},{"key":"2025103105511226100_BST-2025-3017C10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","article-title":"Diagnosis and classification of hematologic malignancies on the basis of genetics","volume":"130","author":"Taylor","year":"2017","journal-title":"Blood"},{"key":"2025103105511226100_BST-2025-3017C11","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2025103105511226100_BST-2025-3017C12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2025103105511226100_BST-2025-3017C13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","article-title":"Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the american society of transplantation and cellular therapy","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant. Cell. Ther"},{"key":"2025103105511226100_BST-2025-3017C14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s11864-024-01237-w","article-title":"Prediction of response to FDA-Approved targeted therapy and immunotherapy in acute Lymphoblastic Leukemia (ALL)","volume":"25","author":"Khawaji","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"2025103105511226100_BST-2025-3017C15","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions","volume":"13","author":"Samra","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"2025103105511226100_BST-2025-3017C16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"2025103105511226100_BST-2025-3017C17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115849","article-title":"AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens","volume":"24","author":"Milnerowicz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"2025103105511226100_BST-2025-3017C18","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","article-title":"Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia","volume":"20","author":"Teachey","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025103105511226100_BST-2025-3017C19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/asheducation-2018.1.137","article-title":"Genetics and prognosis of all in children vs adults","volume":"2018","author":"Roberts","year":"2018","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"2025103105511226100_BST-2025-3017C20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1947601911408076","article-title":"Genetic abnormalities and challenges in the treatment of acute myeloid leukemia","volume":"2","author":"Kumar","year":"2011","journal-title":"Genes Cancer"},{"key":"2025103105511226100_BST-2025-3017C21","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018267","article-title":"The actin cytoskeleton and actin-based motility","volume":"10","author":"Svitkina","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2025103105511226100_BST-2025-3017C22","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022608","article-title":"Microtubules and Microtubule-Associated Proteins","volume":"10","author":"Goodson","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2025103105511226100_BST-2025-3017C23","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.951816","article-title":"Intermediate filaments: Integration of cell mechanical properties during migration","volume":"10","author":"Infante","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"2025103105511226100_BST-2025-3017C24","first-page":"50","article-title":"Disturbing cytoskeleton by engineered nanomaterials for enhanced cancer therapeutics","volume":"29","author":"Xu","year":"2023","journal-title":"Bioact. Mater."},{"key":"2025103105511226100_BST-2025-3017C25","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.21037\/tcr-20-682","article-title":"A review of research progress of antitumor drugs based on tubulin targets","volume":"9","author":"Cheng","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"2025103105511226100_BST-2025-3017C26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450124666230731094837","article-title":"Microtubules and cell division: potential pharmacological targets in cancer therapy","volume":"24","author":"Sebastian","year":"2023","journal-title":"Curr. Drug Targets"},{"key":"2025103105511226100_BST-2025-3017C27","first-page":"5803","article-title":"Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells","volume":"61","author":"Kavallaris","year":"2001","journal-title":"Cancer Res."},{"key":"2025103105511226100_BST-2025-3017C28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11899-019-00501-3","article-title":"Relapsed t cell all: current approaches and new directions","volume":"14","author":"McMahon","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2025103105511226100_BST-2025-3017C29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ejmech.2017.11.062","article-title":"Recent advances in microtubule-stabilizing agents","volume":"143","author":"Cao","year":"2018","journal-title":"Eur. J. Med. Chem"},{"key":"2025103105511226100_BST-2025-3017C30","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"2025103105511226100_BST-2025-3017C31","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1358\/dot.2010.46.9.1519020","article-title":"Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer","volume":"46","author":"Mani","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"2025103105511226100_BST-2025-3017C32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.969183","article-title":"The microtubule cytoskeleton: an old validated target for novel therapeutic drugs","volume":"13","author":"Lafanech\u00e8re","year":"2022","journal-title":"Front. Pharmacol."},{"key":"2025103105511226100_BST-2025-3017C33","doi-asserted-by":"crossref","first-page":"151075","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","author":"\u010cerm\u00e1k","year":"2020","journal-title":"Eur. J. Cell Biol"},{"key":"2025103105511226100_BST-2025-3017C34","first-page":"82","article-title":"Resistance to anti-tubulin agents: from vinca alkaloids to epothilones","volume":"2","author":"Krause","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"2025103105511226100_BST-2025-3017C35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1247\/csf.24.345","article-title":"Stathmin and its phosphoprotein family: general properties, biochemical and functional interaction with tubulin","volume":"24","author":"Curmi","year":"1999","journal-title":"Cell Struct. Funct."},{"key":"2025103105511226100_BST-2025-3017C36","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1091\/mbc.01-07-0362","article-title":"Drosophila stathmin: a microtubule-destabilizing factor involved in nervous system formation","volume":"13","author":"Ozon","year":"2002","journal-title":"Mol. Biol. Cell"},{"key":"2025103105511226100_BST-2025-3017C37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jsb.2006.07.018","article-title":"Structure and thermodynamics of the tubulin-stathmin interaction","volume":"158","author":"Steinmetz","year":"2007","journal-title":"J. Struct. Biol."},{"key":"2025103105511226100_BST-2025-3017C38","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1002\/j.1460-2075.1996.tb00914.x","article-title":"Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics","volume":"15","author":"Marklund","year":"1996","journal-title":"EMBO J."},{"key":"2025103105511226100_BST-2025-3017C39","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1517\/14728222.2011.620951","article-title":"Stathmin: a protein with many tasks. new biomarker and potential target in cancer","volume":"15","author":"Belletti","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"2025103105511226100_BST-2025-3017C40","doi-asserted-by":"crossref","first-page":"660","DOI":"10.5483\/BMBRep.2014.47.12.020","article-title":"Stathmin 1 in normal and malignant hematopoiesis","volume":"47","author":"Machado-Neto","year":"2014","journal-title":"BMB Rep."},{"key":"2025103105511226100_BST-2025-3017C41","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1083\/jcb.200503021","article-title":"Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin","volume":"172","author":"Ng","year":"2006","journal-title":"J. Cell Biol."},{"key":"2025103105511226100_BST-2025-3017C42","doi-asserted-by":"crossref","first-page":"12349","DOI":"10.1074\/jbc.M807761200","article-title":"STAT3-stathmin interactions control microtubule dynamics in migrating T-cells","volume":"284","author":"Verma","year":"2009","journal-title":"J. Biol. Chem."},{"key":"2025103105511226100_BST-2025-3017C43","doi-asserted-by":"crossref","first-page":"29573","DOI":"10.18632\/oncotarget.4998","article-title":"Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells","volume":"6","author":"Machado-Neto","year":"2015","journal-title":"Oncotarget"},{"key":"2025103105511226100_BST-2025-3017C44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0301-472X(03)00043-2","article-title":"Stathmin expression and megakaryocyte differentiation: a potential role in polyploidy","volume":"31","author":"Rubin","year":"2003","journal-title":"Exp. Hematol."},{"key":"2025103105511226100_BST-2025-3017C45","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1182\/blood-2010-09-305540","article-title":"Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production","volume":"117","author":"Iancu-Rubin","year":"2011","journal-title":"Blood"},{"key":"2025103105511226100_BST-2025-3017C46","first-page":"1307","article-title":"Induction of stathmin expression during erythropoietic differentiation","volume":"6","author":"Rabilloud","year":"1995","journal-title":"Cell Growth Differ."},{"key":"2025103105511226100_BST-2025-3017C47","doi-asserted-by":"crossref","first-page":"102522","DOI":"10.1016\/j.bcmd.2020.102522","article-title":"Stathmin 1 deficiency induces erythro-megakaryocytic defects leading to macrocytic anemia and thrombocythemia in Stathmin 1 knock out mice","volume":"87","author":"Ramlogan-Steel","year":"2021","journal-title":"Blood Cells Mol. Dis"},{"key":"2025103105511226100_BST-2025-3017C48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.leukres.2013.11.013","article-title":"Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells","volume":"38","author":"Machado-Neto","year":"2014","journal-title":"Leuk. Res"},{"key":"2025103105511226100_BST-2025-3017C49","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s10637-021-01066-w","article-title":"AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K\/STMN1 axis","volume":"39","author":"Carlos","year":"2021","journal-title":"Invest. New Drugs"},{"key":"2025103105511226100_BST-2025-3017C50","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s10637-021-01197-0","article-title":"STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells","volume":"40","author":"Vicari","year":"2022","journal-title":"Invest. New Drugs"},{"key":"2025103105511226100_BST-2025-3017C51","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2017.e00405","article-title":"Paclitaxel induces stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells","volume":"3","author":"Machado-Neto","year":"2017","journal-title":"Heliyon"},{"key":"2025103105511226100_BST-2025-3017C52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.32604\/biocell.2021.014728","article-title":"STMN1 promotes the proliferation and inhibits the apoptosis of acute myeloid leukemiacells by activating the PI3K\/Akt pathway","volume":"46","author":"Yang","year":"2022","journal-title":"BIOCELL"},{"key":"2025103105511226100_BST-2025-3017C53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bjhh.2017.02.005","article-title":"Stathmin 1 expression in plasma cell neoplasms","volume":"39","author":"Machado-Neto","year":"2017","journal-title":"Rev. Bras. Hematol. Hemoter"},{"key":"2025103105511226100_BST-2025-3017C54","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-1000-z","article-title":"Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years\u2019 discoveries and developments","volume":"14","author":"Biaoxue","year":"2016","journal-title":"J. Transl. Med."},{"key":"2025103105511226100_BST-2025-3017C55","doi-asserted-by":"crossref","first-page":"78994","DOI":"10.18632\/oncotarget.12982","article-title":"Overexpression of stathmin promotes metastasis and growth of malignant solid tumors: a systemic review and meta-analysis","volume":"7","author":"Biaoxue","year":"2016","journal-title":"Oncotarget"},{"key":"2025103105511226100_BST-2025-3017C56","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3892\/or.2012.2157","article-title":"Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma","volume":"29","author":"Liu","year":"2013","journal-title":"Oncol. Rep."},{"key":"2025103105511226100_BST-2025-3017C57","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.3390\/cancers14246080","article-title":"Cellular and molecular effects of eribulin in preclinical models of hematologic neoplasms","volume":"14","author":"Vicari","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025103105511226100_BST-2025-3017C58","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.786","article-title":"Stathmin dynamics modulate the activity of eribulin in breast cancer cells","volume":"9","author":"Yoshie","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"2025103105511226100_BST-2025-3017C59","doi-asserted-by":"crossref","first-page":"173853","DOI":"10.1016\/j.ejphar.2021.173853","article-title":"Synthetic cyclopenta[b]indoles exhibit antineoplastic activity by targeting microtubule dynamics in acute myeloid leukemia cells","volume":"894","author":"Vicari","year":"2021","journal-title":"Eur. J. Pharmacol"},{"key":"2025103105511226100_BST-2025-3017C60","doi-asserted-by":"crossref","first-page":"105856","DOI":"10.1016\/j.tiv.2024.105856","article-title":"Cyclopenta[b]indoles as novel antimicrotubule agents with antileukemia activity","volume":"99","author":"Vicari","year":"2024","journal-title":"Toxicol. In Vitro"},{"key":"2025103105511226100_BST-2025-3017C61","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrm2866","article-title":"Organizing the cell cortex: the role of ERM proteins","volume":"11","author":"Fehon","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2025103105511226100_BST-2025-3017C62","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ceb.2011.04.011","article-title":"Ezrin, Radixin and Moesin: key regulators of membrane-cortex interactions and signaling","volume":"23","author":"Neisch","year":"2011","journal-title":"Curr. Opin. Cell Biol."},{"key":"2025103105511226100_BST-2025-3017C63","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.588801","article-title":"Ezrin mediates invasion and metastasis in tumorigenesis: a review","volume":"8","author":"Song","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"2025103105511226100_BST-2025-3017C64","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1073\/pnas.96.13.7300","article-title":"Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase\/Akt pathway","volume":"96","author":"Gautreau","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2025103105511226100_BST-2025-3017C65","first-page":"1","article-title":"Ezrin orchestrates signal transduction in airway cells","volume":"174","author":"Yin","year":"2018","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"2025103105511226100_BST-2025-3017C66","doi-asserted-by":"crossref","first-page":"13025","DOI":"10.1021\/bi061064a","article-title":"Cooperative adsorption of ezrin on PIP2-containing membranes","volume":"45","author":"Herrig","year":"2006","journal-title":"Biochemistry"},{"key":"2025103105511226100_BST-2025-3017C67","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1242\/jcs.133108","article-title":"ERM proteins in cancer progression","volume":"127","author":"Clucas","year":"2014","journal-title":"J. Cell. Sci."},{"key":"2025103105511226100_BST-2025-3017C68","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2567.2004.01882.x","article-title":"Ezrin\/radixin\/moesin proteins and Rho GTPase signalling in leucocytes","volume":"112","author":"Ivetic","year":"2004","journal-title":"Immunology"},{"key":"2025103105511226100_BST-2025-3017C69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081996","article-title":"Two Sides of the Coin: ezrin\/radixin\/moesin and merlin control membrane structure and contact inhibition","volume":"20","author":"Michie","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"2025103105511226100_BST-2025-3017C70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10585-006-9033-y","article-title":"Ezrin mediates growth and survival in ewing\u2019s sarcoma through the AKT\/mTOR, but not the MAPK, signaling pathway","volume":"23","author":"Krishnan","year":"2006","journal-title":"Clin. Exp. Metastasis"},{"key":"2025103105511226100_BST-2025-3017C71","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-019-0383-z","article-title":"Ezrin promotes breast cancer progression by modulating AKT signals","volume":"120","author":"Li","year":"2019","journal-title":"Br. J. Cancer"},{"key":"2025103105511226100_BST-2025-3017C72","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1369\/0022155411418661","article-title":"Expression of ezrin in human embryonic, fetal, and normal adult tissues","volume":"59","author":"Xie","year":"2011","journal-title":"J. Histochem. Cytochem"},{"key":"2025103105511226100_BST-2025-3017C73","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/labinvest.3780174","article-title":"Altered expression of the ERM proteins in lung adenocarcinoma","volume":"80","author":"Tokunou","year":"2000","journal-title":"Lab. Invest."},{"key":"2025103105511226100_BST-2025-3017C74","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/onc.2011.245","article-title":"Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells","volume":"31","author":"Bulut","year":"2012","journal-title":"Oncogene"},{"key":"2025103105511226100_BST-2025-3017C75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/futurepharmacol3010005","article-title":"Perspectives for targeting ezrin in cancer development and progression","volume":"3","author":"Lipreri da Silva","year":"2023","journal-title":"Future Pharmacology"},{"key":"2025103105511226100_BST-2025-3017C76","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/cells12121620","article-title":"Ez-metastasizing: the crucial roles of ezrin in metastasis","volume":"12","author":"Buenaventura","year":"2023","journal-title":"Cells"},{"key":"2025103105511226100_BST-2025-3017C77","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s13402-021-00621-0","article-title":"Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia","volume":"44","author":"Lipreri da Silva","year":"2021","journal-title":"Cell. Oncol."},{"key":"2025103105511226100_BST-2025-3017C78","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2007-09-110510","article-title":"Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia","volume":"111","author":"Monni","year":"2008","journal-title":"Blood"},{"key":"2025103105511226100_BST-2025-3017C79","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/10715762.2012.733385","article-title":"FLT3-driven redox-modulation of Ezrin regulates leukaemic cell migration","volume":"47","author":"Corcoran","year":"2013","journal-title":"Free Radic. Res."},{"key":"2025103105511226100_BST-2025-3017C80","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jprot.2012.09.009","article-title":"Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors","volume":"78","author":"Habif","year":"2013","journal-title":"J. Proteomics"},{"key":"2025103105511226100_BST-2025-3017C81","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/10428194.2010.538776","article-title":"WAVE1 regulates P-glycoprotein expression via Ezrin in leukemia cells","volume":"52","author":"Yang","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"2025103105511226100_BST-2025-3017C82","doi-asserted-by":"crossref","first-page":"177161","DOI":"10.1016\/j.ejphar.2024.177161","article-title":"Pharmacological inhibition of ezrin reduces proliferative and invasive phenotype in acute lymphoblastic leukemia cells","volume":"987","author":"Lipreri da Silva","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"2025103105511226100_BST-2025-3017C83","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/leu.2015.86","article-title":"Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma","volume":"29","author":"Pore","year":"2015","journal-title":"Leukemia"},{"key":"2025103105511226100_BST-2025-3017C84","doi-asserted-by":"crossref","first-page":"121146","DOI":"10.1016\/j.lfs.2022.121146","article-title":"Ezrin is highly expressed and a druggable target in chronic lymphocytic leukemia","volume":"311","author":"Lipreri da Silva","year":"2022","journal-title":"Life Sci. (1962)"}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/53\/05\/1249\/978355\/bst-2025-3017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/53\/05\/1249\/978355\/bst-2025-3017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:51:26Z","timestamp":1761904286000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/53\/05\/1249\/236564\/New-molecular-targets-in-acute-leukemias"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":84,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,9,22]]},"published-print":{"date-parts":[[2025,10,29]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20253017","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,22]]}}}